127.26 +0.43 (0.34%)
Pre-market: 6:25AM EDT
|Bid||126.54 x 100|
|Ask||127.65 x 100|
|Day's range||125.78 - 127.30|
|52-week range||122.15 - 148.32|
|PE ratio (TTM)||267.57|
|Earnings date||17 Jul 2018|
|Forward dividend & yield||3.36 (2.57%)|
|1y target est||149.05|
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.
Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.
"I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.
A campaign to boost British businesses with a social mission has attracted major names, from banking to pharmaceuticals, but is far from its goal of channelling 1 billion pounds ($1.4 billion) into the sector by 2020, its founders said on Wednesday. Pharmaceutical company Johnson & Johnson (NYSE: JNJ - news) , consulting firm PwC and Santander bank have signed up to the Buy Social Corporate Challenge, launched in 2016 by Social Enterprise UK (SEUK), which represents the growing sector. About a dozen companies participating in the scheme have spent a total of 45 million pounds over the last two years with organisations that aim to address social and environmental issues as well as making a profit, SEUK said on Wednesday.
The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.
Johnson & Johnson reported higher-than-expected sales in its latest quarter and boosted its sales outlook for the year despite ongoing pricing pressures for its prescription drugs and medical devices. J&J said it planned to cut costs in its supply chain by $600 million to $800 million a year by 2022. To carry out the changes, J&J expects it will take $1.9 billion to $2.3 billion in charges over the next several years.
Trade, taxes and China are the main themes to watch for heading into first-quarter earnings, along with a spate of potential deals.
Stocks that moved substantially or traded heavily Tuesday: UnitedHealth Group Inc., up $8.23 to $238.55 The health insurer raised its annual profit forecast after a strong first quarter. Tesla Inc., down ...
U.S. stock indexes rallied on Tuesday on broad-based gains while Netflix and UnitedHealth earnings impressed investors and boosted optimism about the U.S. corporate reporting season. Shares in Netflix (NFLX.O), the first of Wall Street's leading momentum stocks to report earnings, rose 9 percent to close at a record high after the video-streaming pioneer smashed analysts' quarterly subscriber estimates. Amazon.com (AMZN.O) was the S&P's biggest boost with a 4 percent jump, helped by Netflix results but also by signs the U.S. Supreme Court is hesitant to let states force out-of-state online retailers to collect sales taxes on purchases.
Johnson & Johnson nudged its 2018 sales guidance higher Tuesday as demand for cancer drugs surged in the first quarter, even as its blockbuster Remicade continued to face competitive pressure.